

INDEX

SESSION 1	13
INTEGRATING DRUG UTILIZATION STUDIES IN A WIDER EUROPE	14
POSSIBILITIES FOR INFORMATION EXCHANGE ON NATIONAL REGISTERS ON DRUG USE DATA IN EUROPE	16
MEASURING THE EFFECT OF INTERVENTIONS TO PROMOTE RATIONAL PRESCRIBING	17
LINKING MICRO- AND MACRO- UTILIZATION DATA	18
SESSION 2	21
ATC/DDD A GLOBAL STANDARD FOR DRUG CLASSIFICATION AND UTILIZATION RESEARCH	22
WHO ESSENTIAL DRUGS AND MEDICINES POLICY: THE ROLE OF DRUG UTILIZATION	23
AVAILABILITY OF DRUG UTILISATION DATA IN DEVELOPING COUNTRIES	24
INTERNATIONAL COMPARISONS OF ANTIHYPERTENSIVE DRUG USE	25
SUMMING UP: TOWARDS A GLOBAL DRUG UTILIZATION NETWORK	26
SESSION 2B	27
OTITIS MEDIA: DIFFERENT PATTERNS OF PRESCRIPTION IN BULGARIA, RUSSIA, SLOVAKIA AND SPAIN	28
PREVALENCE OF ANTIBIOTICS AMONG RUSSIAN NON-MEDICAL POPULATION - RESULT OF PROSPECTIVE PHARMACOEPIDEMIOLOGICAL STUDY	29
PROMOTION OF RATIONAL ANTIBIOTIC USE IN FLEMISCH GENERAL PRACTICE: IMPLEMENTATION OF A GUIDELINE FOR ACUTE COUGH	30
PATTERNS OF DRUG PRESCRIBING IN ADULTS WITH ACUTE OTITIS MEDIA AN ACUTE SINUSITIS (AS)	32
WHAT DO RUSSIAN GPs ACTUALLY KNOW ABOUT THE ETIOLOGY AND TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA (CAP)?	33
ANTIBIOTIC USE IN HOSPITAL CARE – A MODEL FOR QUALITY ASSESSMENT	35
PARACETAMOL (ACETAMINOPHEN) AND ANTIBIOTICS, THE FREQUENCY OF USE AMONG PRE-SCHOOL CHILDREN	36

SESSION 3	39
EUROPEAN SURVEILLANCE OF ANTIBIOTIC CONSUMPTION (ESAC)	40
DRUG UTILIZATION OF ANTIBACTERIALS – A COMPARISON BETWEEN DIFFERENT EUROPEAN COUNTRIES	42
METHODOLOGICAL PROBLEMS IN COLLECTING COMPARABLE ANTIBACTERIAL UTILIZATION DATA	43
RELATIONSHIP BETWEEN ASTHMA CONTROL AND COTHERAPY FOR CONCOMITANT DISEASES	44
ANTIBACTERIAL DRUG USE IN CHILDREN WITH ACUTE RESPIRATORY INFECTIONS - 3 YEAR PHARMACOEPIDEMIOLOGICAL STUDY	45
EVALUATION OF INDIVIDUAL EXPOSURE TO THE ANTIMICROBIALS IN THE HOSPITAL SETTING – AN IMPORTANT TOOL FOR THE INTERPRETING RESULTS OF LOCAL ANTIMICROBIAL RESISTANCE SURVEILLANCE	47
MINIMAL DATASET FOR THE EVALUATION OF GUIDELINES ON ANTIBIOTICS (EGA-STUDY)	49
 SESSION 3B	 51
USE AND COST OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS: DIFFERENCES BETWEEN ITALY AND GERMANY	52
ANTI-ASTHMATIC DRUG UTILIZATION AND ASTHMA MORTALITY*	53
ECOTOXICOLOGICAL IMPACT OF DRUGS: THE NEED FOR DRUG UTILIZATION MONITORING	54
IMPACT OF AGE AND GENDER ON THE UTILIZATION OF REIMBURSED AMBULATORY PHARMACEUTICALS IN BELGIUM: HISTORICAL REVIEW 1986 - 1999	55
USING THE GENERAL PRACTICE RESEARCH DATABASE (GPRD) FOR COHORT STUDIES IN PHARMACOEPIDEMIOLOGY: PROBLEMS IN DEFINING THE DENOMINATOR POPULATION	56
INFLUENCE OF THE USED DETERMINATION METHOD ON THE ADHERENCE TO ANTIRETROVIRAL THERAPY ESTIMATION	57
 SESSION 4	 59
INTRODUCTION OF SESSION 4	60
THE EXPERIENCE IN DEVELOPING PHARMACOEPIDEMIOLOGICAL RESEARCH IN THE CZECH REPUBLIC	61
DIFFICULTIES OF DRUG UTILIZATION RESEARCH IN HUNGARY	64
UTILIZATION OF ANTI-ASTHMATICS AND ACUTE ASTHMA MORTALITY IN THE CZECH REPUBLIC IN 1970-1997	65

PROTON PUMP INHIBITORS AS THE MOST EFFECTIVE INHIBITORS OF GASTRIC SECRETION AND PHARMACO-ECONOMICAL ASPECTS OF THE TREATMENT OF GASTRODUODENAL ULCER DISEASES	66
THE DIFFERENCES BETWEEN PRESCRIBED DAILY DOSES AND DEFINED DAILY DOSES OF ANTIEPILEPTIC	67
ROUTINE HYPERTENSION MANAGEMENT IN BELARUS: QUALITY OF LIFE-, GENDER- AND LIFE-STYLE IMPACT ON DRUG CHOICE AND COMPLIANCE	68
PHARMACOEPIDEMIOLOGICAL STUDY OF BRONCHODILATORS AND ANTI-INFLAMMATORY ANTI-ASTHMA AGENTS IN PEDIATRIC OUT-PATIENT CLINICS OF THE CITY OF KAZAN	69
WORKSHOP I.	71
IMPROVING DRUG PRESCRIBING BY USE OF QUALITY INDICATORS AND FEED BACK	72
SESSION 5	73
INTRODUCTION OF SESSION 5	74
DRUG RELATED MORBIDITY & MORTALITY AND THE INSTITUTE OF MEDICINE (IOM) REPORTS	75
ATTITUDES OF GPs AND SPECIALISTS REGARDING THERAPEUTIC GUIDELINES FOR TRANSMURAL CARE	76
A BIBLIOMETRIC STUDY OF DRUG UTILIZATION RESEARCH IN THE ABSTRACT BOOKS OF THE INTERNATIONAL CONFERENCE OF PHARMACOEPIDEMIOLOGY : 1997-1999	77
GASTROINTESTINAL DRUG USE IN PATIENTS WITH DIABETES IN PRIMARY CARE	79
BENEFITS AND RISKS OF ANTIDEPRESSANTS IN HOSPITAL USE	80
DRUG UTILIZATION RESEARCH AND MONITORING IN DENMARK	81
SESSION 5B	83
FOCUS GROUP DISCUSSIONS - A TOOL FOR EXPLORING UNANTICIPATED ISSUES	84
COUNSELLING PATIENTS WITH PAIN AS A PREREQUISITE TO IMPLEMENTING PHARMACEUTICAL CARE: RESULTS OF A DATABASED QUALITY CIRCLE OF PHARMACISTS IN SAXONY	85
A SET OF INDICATORS TO ASSESS THE SUCCESS OF AN INTERVENTION TO IMPROVE THE PRESCRIBING QUALITY OF LIPID LOWERING DRUGS	86
DISEASE SEVERITY AND ADHERENCE TO HEART FAILURE GUIDELINES IN GENERAL PRACTICE	87

FROM DRUG PRESCRIPTION TO PRESCRIBING REPORTS	88
PREVALENCE OF UNDERDOSING IN AMBULATORY PHARMACOTHERAPY	89
APPLYING QUALITY INDICATORS ON PRESCRIPTION DATA FOR THE ROUTINE EVALUATION OF DRUG USE APPROPRIATENESS	90
DRUG PRESCRIPTION IN TWO DIFFERENT MODELS OF PRIMARY CARE CENTERS	91
SESSION 6	93
COLLECTING DATA ABOUT MEDICINES IN THE EUROPEAN COUNTRIES: RESULTS FROM THE EURO-MEDICINES PROJECT	94
CO-OPERATION BETWEEN DRUG INFORMATION CENTRES (DICS) AND DRUG UTILIZATION RESEARCH GROUPS (DURGS) ON THE NATIONAL LEVEL	95
INTERNET DRUG DATABASE AND STATISTICAL ANALYSES USING OF DRUGS	96
PATIENT INFORMATION LEAFLETS APPROPRIATE DRUG INFORMATION OR A SOURCE OF CONFUSION?	97
NORDIC COMPARISON OF THE USE OF ATC AND DDDS	98
JANUS - A RELIABLE TIME SAVING TOOL IN DRUG PRESCRIBING.	99
COMPASS- A GUIDE FOR GENERAL PRACTITIONERS ON THEIR PRESCRIBING	100
WORKSHOP II.	101
THE USERS' PERSPECTIVE ON MEDICINES - FINDING NEW AREAS	102
POSTERS	105
ATC/DDD	
A1. MEDICINES FOR CHILDREN - COMPOUNDING IN NORWEGIAN HOSPITAL PHARMACIES	106
A2. DRUG UTILIZATION ON ANTIDIABETIC DRUGS IN NORWAY	108
A3. MARKED DIFFERENCES IN COSTS FOR NSAIDS BETWEEN CROATIA AND SWEDEN	109
A4. DRUG CONSUMPTION MONITORING IN THE UNIVERSITY HOSPITAL CENTRE ZAGREB	110
Antibiotics Utilization	
B1. ANTIBIOTIC CONSUMPTION IN A TERTIARY HOSPITAL IN ISRAEL	111

B2. ANTIMICROBIAL CONSUMPTION IN POLYVALENT INTENSIVE CARE UNIT	112
B3. ANTIBIOTIC CONSUMPTION CHANGES IN THE FACULTY HOSPITAL IN OLOMOUC DURING 1997-1999	113
B4. CEPHALOSPORIN USE: DIFFERENCES BETWEEN ENGLAND AND ITALY	114
B5. DIFFERENT USE OF ANTIBIOTICS IN EUROPE: THE ROLE OF CULTURAL FACTORS	115
B6. THERAPY OF ACUTE TONSILLITIS IN THE HODONÍN REGION	116
B7. ANTIBIOTIC POLICY AND ITS ROLE IN PREVENTION OF NOSOCOMIAL INFECTIONS	117
B8. BACTERIAL RESISTANCE AND THE USE OF ANTIBIOTICS IN SURGICAL AND MEDICAL DEPARTMENTS	118
B9. THE CONSUMPTION OF ANTIBIOTICS AND RESISTANCE OF BACTERIAL ISOLATES IN THE INTENSIVE CARE UNITS AT THE UNIVERSITY TEACHING HOSPITAL IN HRADEC KRÁLOVÉ, CZECH REPUBLIC	119
B10. CONSUMPTION TRENDS OF ANTIMICROBIAL DRUGS AND RECENT CHANGES IN THE MICROBIAL RESISTANCE PATTERN IN THE CZECH REPUBLIC	121
B11. UTILIZATION OF ANTIBIOTICS IN BELGIUM	122
B12. EVOLUTION OF TUBERCULOSIS TREATMENT IN SPAIN 1993-1998	123

DUR in Central and Eastern European Countries

C1. SURVEY OF THE CENTRALIZED DRUG PURCHASING IN THE REPUBLIC OF ARMENIA	124
C2. ANALYSIS OF DRUG CONSUMPTION IN FOUR CENTRAL EUROPEAN COUNTRIES	125
C3. INAPPROPRIATE MEDICATION USE IN COMMUNITY-RESIDING ELDERLY LIVING IN ISFAHAN – BACKGROUND, METHODOLOGY AND CHALLENGES	127
C4. COMPARATIVE ANALYSIS OF THE REGISTERED PSYCHOTROPIC DRUGS BETWEEN LIBYA AND BULGARIA	129
C5. TRENDS IN CONSUMPTION OF INSULIN AND PERORAL ANTIDIABETIC DRUGS IN CZECH REPUBLIC 1997-2000	130
C6. THE PHARMACOTHERAPY IN THE TREATMENT OF ISCHAEMIC HEART DISEASE IN HOSPITAL CONDITIONS	131
C7. DRUG UTILIZATION OF »ANTI-ASTHMA« DRUGS IN THE REGIONAL PEDIATRIC POPULATION	132

C8. PRESCRIBING PATTERNS ANALYSIS – CROSS COUNTRY VARIATIONS IN BULGARIA, ROMANIA, MACEDONIA AND BOSNIJA HERZEGOVINA	133
C9. ANALYSIS OF CONSUMPTION AND COSTS OF PRESCRIPTION DRUGS USED ON CORONARY UNITS	134
C10. CARDIOVASCULAR DISEASES – PHARMACOTHERAPY	135
C11. RECENT TRENDS OF CARDIOVASCULAR DRUGS CONSUMPTION IN THE CZECH REPUBLIC	136
C12. REAL DRUGS PRESCRIPTION PRACTICE IN THE RUSSIAN LARGE SPECIALIZED OUTPATIENT CLINIC: THE FREQUENCY OF POLYPHARMACY AND CONFORMITY TO THE NATIONAL LIST OF ESSENTIAL DRUGS	137
C13. UTILIZATION OF FREE AND PRIVILEGED PRESCRIBED DRUGS IN THE BIG CITY ON THE SOUTHWEST OF RUSSIA: STRUCTURE OF THE CHARGES DEPENDING ON DEFINED GROUPS OF THE PATIENTS	138
C14. COMPARISON OF DRUG UTILIZATION IN TREATING ACUTE MYOCARDIAL INFARCTION IN TWO HOSPITALS IN YUGOSLAVIA	139
C15. CONSUMPTION OF PSYCHOTROPIC DRUGS IN MILITARY MEDICAL ACADEMY-BELGRADE, DURING THE TEN YEARS PERIOD (1990-2000)	140
C16. TRENDS IN CONSUMPTION OF CALCIUM CHANNEL BLOCKERS IN CZECH REPUBLIC 1992-1999 AND COMPARISON WITH SELECTED COUNTRIES	141
C17. CONSUMPTION OF HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE IN HUNGARY (1990-1999)	142
C18. THE CONSUMPTION OF DRUGS FOR THE MANAGEMENT OF PEPTIC ULCER DISEASE IN THE REGION OF HRADEC KRÁLOVÉ, CZECH REPUBLIC	143
State of the Art of Drug	
D1. ADVERSE DRUG REACTION MONITORING - ASSESSMENT OF LIPID LOWERING AGENTS ASSOCIATED REACTIONS IN JENA	145
D2. USE OF ANTIDIABETIC DRUGS IN SPAIN DURING THE PERIOD 1989-1998	146
D3. STUDY OF DRUGS PRESCRIBED TO THE ECONOMICALLY WEAK PATIENTS (DESTITUTE)	147
D4. PREVALENCE OF SELF-MEDICATION IN RURAL AREAS OF PORTUGAL – A PILOT STUDY	148
D5. EVALUATION OF PRESCRIPTION AND PATIENT ATTITUDES IN ANTIHYPERTENSIVE DRUG USE AND THE ROLE OF THE PHARMACISTS IN 13 URBAN AREAS	149

D6. CHILDURG: THE EURODURG WORKING GROUP FOR DRUG USE IN CHILDREN	150
D7. DRUG USE IN CHILDREN IN TENERIFE (SPAIN): A COMPARISON 15 YEARS LATER	151
D8. A PILOT STUDY OF A COMMUNITY APPROACH TO THE CONTROL OF HEAD LICE INFESTATION IN 3 INNER CITY PRIMARY SCHOOLS IN BELGIUM	152
D9. DEEP VENOUS THROMBOSIS OF LOW EXTREMITIES: PHARMACOECONOMIC ASPECTS OF THE THERAPY	153
D10. RELEVANCE OF DRUG UTILIZATION DATA IN PHARMACOVIGILANCE	154
D11. PHARMACOEPIDEMIOLOGICAL STUDY OF NEUROLEPTIC- -INDUCED EXTRAPYRAMIDAL DISORDERS AT THE REPUBLICAN PSYCHIATRIC HOSPITAL OF THE REPUBLIC OF TATARSTAN	155
D12. A STUDY OF URINARY CULTURE&ANTIBIOGRAM IN IRANIAN CHILDREN WITH URINARY TRACT INFECTION	157
D13. THE INFLUENCE OF ENALAPRIL ON LEFT VENTRICULAR HYPERTROPHY AND QT DISPERSION IN PATIENTS WITH ESSENTIAL HYPERTENSION	158
D14. PATIENT INFORMATION LEAFLET READABILITY TEST	159
D15. MEDICAL-ECONOMICAL VIEW ON PHARMACOTHERAPY OF PEPTIC DISEASES IN CONNECTION WITH HELICOBACTER PYLORI INFECTION	160
D16. THE EFFECT OF ESTROGEN ON GRAFT REJECTION EVENTS	161
D17. DRUG DATA PROCESSING IN THE JOINT ANALYSIS OF THE MONICA OPTIONAL STUDY ON DRUGS	162

Drug Information and Drug Utilization Research

E1. DRUG POLICY – NEW RULES OF PROCEDURE OF THE COMMITTEE OF MINISTRY OF HEALTH FOR DRUG CATEGORISATION	164
E2. ELICITING STAKEHOLDER PREFERENCES IN THE DEVELOPMENT OF A TOOL FOR THE SUPPORT OF COMPUTERISED REPEAT PRESCRIBING MANAGEMENT IN UK GENERAL PRACTICE	165
E3. ANTIPSYCHOTICS AVAILABLE IN THE EUROPEAN UNION	166
E4. THE KNOWLEDGE OF CARDIOVASKULAR DRUGS INTERACTIONS IN EVERYDAY MEDICAL PRACTICE	168
E5. PHARMACOTHERAPEUTICAL INFORMATION	169
E6. ESTABLISHING THERAPY TRADITIONS FOR CARDIOVASCULAR DRUGS	170
E7. THE CONCEPT OF THE OPTIMIZED HOSPITAL FORMULARY	171

E8. FINNISH DATABASES ON DRUG UTILIZATION	172
E9. THE SWEDISH »BIBLE« ON DRUG UTILIZATION	173
E10. TRENDS IN THE USE OF ANTIHYPERTENSIVES IN SPAIN (1995-1999)	174
SPEAKEARS' ADDRESSES	175
LIST OF AUTHORS	183